PALI +500% potential according to this analyst
Palisade Bio, Inc. (PALI) plans to initiate a phase 3 study for accelerating the return of bowel function in the first half of 2022 and for the first patient to be enrolled in the second half of 2022.
On 2/2/2022 LADENBURG THALM/SH SH brokerage Initiated Coverage for PALI with a Buy rating and $5.00 Price Target.
Market Cap 12.841Mil
52 Week Range 0.76 - 16.02
I think this stock can easily double in price this year.
On 2/2/2022 LADENBURG THALM/SH SH brokerage Initiated Coverage for PALI with a Buy rating and $5.00 Price Target.
Market Cap 12.841Mil
52 Week Range 0.76 - 16.02
I think this stock can easily double in price this year.
BUYSELL indicators tradingindicators.store/
TRADING COURSE bit.ly/tradex
Private Signals patreon.com/PremiumOptionsSignals
RESULTS bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880
TRADING COURSE bit.ly/tradex
Private Signals patreon.com/PremiumOptionsSignals
RESULTS bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880
Thông báo miễn trừ trách nhiệm
Thông tin và ấn phẩm không có nghĩa là và không cấu thành, tài chính, đầu tư, kinh doanh, hoặc các loại lời khuyên hoặc khuyến nghị khác được cung cấp hoặc xác nhận bởi TradingView. Đọc thêm trong Điều khoản sử dụng.